Secukinumab and etanercept are associated with an increased risk for anterior uveitis in patients with spondyloarthritis, compared with monoclonal TNF inhibitors, according to data published in the Annals of the Rheumatic Diseases.
“For [anterior uveitis (AU)], TNF inhibitors reduce the frequency of flares in [axial SpA], and the presence of AU has been linked to a better TNF inhibitors treatment retention, but the protective effects regarding AU seem to be less for etanercept than for monoclonal TNF inhibitors,” Ulf Lindström, MD, PhD, of the University of Gothenburg, in